Genzyme: Analysts' Upgrades, Downgrades

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Ensco (ESV) upgraded at MKM from Neutral to Buy. $56 price target. A recovery is expected in the international jackup market.

GSI Commerce (GSIC) upgraded at Morgan Stanley to Overweight. $26 price target. Company is gaining market share and should be able to realize cross-selling benefits.

STOCK COMMENTS / EPS CHANGES

Advanced Micro (AMD) numbers increased at FBR. Shares of AMD now seen reaching $9. Estimates also boosted, as the debt recapitalization will pay off. That said, PC checks are worsening. Market Perform rating.

Conagra (CAG) estimates, target boosted at UBS. Shares of CAG now seen reaching $26. Estimates also raised, to reflect higher demand for eating at home. Buy rating.

Chico's FAS (CHS) numbers increased at FBR. Shares now seen reaching $18. Estimates also raised, to reflect the company's strong sales momentum. Outperform rating.

Campbell Soup (CPB) numbers raised at UBS. CPB shares now seen reaching $34. Estimates also raised, to reflect improving execution and business momentum. Neutral rating.

China Sunergy (CSUN) price target raised at Barclays. CSUN price target increased to $5 from $4.50 on strong 4Q guidance. 2009 and 2010 EPS estimates lifted to -$0.07 from -$0.30 and to $0.50 from $0.45, respectively. Equal Weight rating.

Dover (DOV) estimates, target raised at Morgan Stanley. Shares of DOV now seen reaching $50. Estimates also boosted, to reflect further cost-cutting efforts. Overweight rating.

Family Dollar (FDO) estimates raised at Goldman through 2012. Buyback program should help add to earnings. Neutral rating and $31 price target.

Genzyme (GENZ) estimates reduced at Goldman through 2011. Company seeing lower product sales for Renagel and Renvela. Myozyme may also be delayed. Sell rating and $44 price target.